Novartis reports positive topline results from the first Phase III trial of Beovu versus aflibercept in patients with diabetic macular edema (DME)

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post